Sunshine Biopharma 미래 성장

Future 기준 확인 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Sunshine Biopharma.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Biotechs 수익 성장	27.1%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	20 Aug 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Mar 14

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Jan 29

Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Sep 12

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Sunshine Biopharma 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

NasdaqCM:SBFM - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2024	44	N/A	N/A	N/A	1
6/30/2024	30	-4	-12	-11	N/A
3/31/2024	27	-4	-11	-10	N/A
12/31/2023	24	-5	-10	-9	N/A
9/30/2023	20	-27	-9	-8	N/A
6/30/2023	15	-28	-10	-9	N/A
3/31/2023	9	-27	-6	-6	N/A
12/31/2022	4	-27	-6	-5	N/A
9/30/2022	0	-3	-3	-3	N/A
6/30/2022	0	-5	-3	-3	N/A
3/31/2022	0	-7	-3	-3	N/A
12/31/2021	0	-12	-2	-2	N/A
9/30/2021	0	-14	-2	-2	N/A
6/30/2021	0	-11	-1	-1	N/A
3/31/2021	0	-9	-1	-1	N/A
12/31/2020	0	-3	-1	-1	N/A
9/30/2020	0	-2	0	0	N/A
6/30/2020	0	-2	0	0	N/A
3/31/2020	0	-1	0	0	N/A
12/31/2019	0	-1	0	0	N/A
9/30/2019	0	-1	0	0	N/A
6/30/2019	0	-2	-1	-1	N/A
3/31/2019	0	-2	-1	-1	N/A
12/31/2018	N/A	-2	-1	-1	N/A
9/30/2018	N/A	-2	-1	-1	N/A
6/30/2018	N/A	-1	-1	-1	N/A
3/31/2018	0	-1	N/A	-1	N/A
12/31/2017	N/A	-1	N/A	-1	N/A
9/30/2017	N/A	-2	N/A	0	N/A
6/30/2017	N/A	-3	N/A	0	N/A
3/31/2017	N/A	-3	N/A	0	N/A
12/31/2016	N/A	-3	N/A	0	N/A
9/30/2016	N/A	-3	N/A	-1	N/A
6/30/2016	N/A	-2	N/A	-1	N/A
3/31/2016	0	-2	N/A	-1	N/A
12/31/2015	0	-2	N/A	-1	N/A
9/30/2015	0	-1	N/A	-1	N/A
6/30/2015	0	-1	N/A	-1	N/A
3/31/2015	N/A	-2	N/A	-1	N/A
12/31/2014	N/A	-2	N/A	-1	N/A
9/30/2014	N/A	-2	N/A	0	N/A
6/30/2014	N/A	-2	N/A	0	N/A
3/31/2014	N/A	-2	N/A	0	N/A

애널리스트 미래 성장 예측

수입 대 저축률: Insufficient data to determine if SBFM's forecast earnings growth is above the savings rate (2.5%).

수익 vs 시장: Insufficient data to determine if SBFM's earnings are forecast to grow faster than the US market

고성장 수익: Insufficient data to determine if SBFM's earnings are expected to grow significantly over the next 3 years.

수익 대 시장: Insufficient data to determine if SBFM's revenue is forecast to grow faster than the US market.

고성장 수익: Insufficient data to determine if SBFM's revenue is forecast to grow faster than 20% per year.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: Insufficient data to determine if SBFM's Return on Equity is forecast to be high in 3 years time

Sunshine Biopharma 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Sunshine Biopharma, Inc., Annual General Meeting, Dec 10, 2024

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Sunshine Biopharma, Inc. announced delayed 10-Q filing

Sunshine Biopharma Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Nasdaq Staff Determines to Delist Sunshine Biopharma's Securities Pursuant to its Discretionary Authority Under Listing Rule 5101

Nasdaq Staff Determines to Delist Sunshine Biopharma's Securities Pursuant to its Discretionary Authority Under Listing Rule 5101

Sunshine Biopharma, Inc. announced delayed 10-Q filing

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Sunshine Biopharma Announces Update on Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

New major risk - Shareholder dilution

New major risk - Share price stability

Sunshine Biopharma, Inc. Announces Executive Changes

Sunshine Biopharma, Inc. Announces Executive Changes

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Third quarter 2023 earnings: EPS exceeds analyst expectations

Sunshine Biopharma, Inc., Annual General Meeting, Dec 07, 2023

Sunshine Biopharma Receives 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Sunshine Biopharma, Inc. announced that it has received CAD 5 million in funding

First quarter 2023 earnings released: US$0.077 loss per share (vs US$0.23 loss in 1Q 2022)

Full year 2022 earnings released: US$1.76 loss per share (vs US$4.76 loss in FY 2021)

Sunshine Biopharma, Inc. (NasdaqCM:SBFM) announces an Equity Buyback for $2 million worth of its shares.

Sunshine Biopharma Receives Non-Compliance Notice From Nasdaq

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$1.59 loss in 3Q 2021)

Sunshine Biopharma, Inc. (NasdaqCM:SBFM) completed the acquisition of Nora Pharma Inc. from Malek Chamoun.

Sunshine Biopharma acquires Nora Pharma for C$30M

We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Second quarter 2022 earnings released: US$0.034 loss per share (vs US$1.20 loss in 2Q 2021)

Sunshine Biopharma reports 1H results

First quarter 2022 earnings released: US$0.23 loss per share (vs US$2.82 loss in 1Q 2021)

Sunshine Biopharma, Inc. Files Patent Application Announces mRNA Molecules

Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs

Sunshine Biopharma, Inc.’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells

Less than half of directors are independent

Sunshine Biopharma Common Stock Deleted from Other OTC

Sunshine Biopharma Mice Study for Covid-19 Treatment Progressing as Planned

Sunshine Biopharma, Inc.’s Adva-27a Destroys Cancer Cells Expressing P-glycoprotein, a Marker Present in Over 50% of All Cancer Types

Sunshine Biopharma, Inc. announced that it has received $0.5 million in funding from RB Capital Partners, Inc.

Sunshine Biopharma Receives Recently Ordered New Batch of Adva-27a and Initiates QA/QC Testing

Sunshine Biopharma, Inc. announced delayed 10-Q filing

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견